Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Histone deacetylase (HDAC) inhibitors induce cell cycle arrest and differentiation in cancer cells and have been in Phase I-II clinical trials for the treatment of various solid or haematological malignancies. In recent years, HDAC inhibitors have emerged as potent contenders for anti-inflammatory drugs, offering new lines of therapeutic intervention for rheumatoid arthritis or lupus erythematosus. The molecular mode of action of HDAC inhibitors is still controversial but seems to rely on reduced inflammatory mediator production, such as nitric oxide or cytokines, which implies inhibition of the transcription factor NF-kappaB. These anti-inflammatory effects will hopefully lead us to appreciate the complex anti-tumour effects of HDAC inhibitors.
Blanchard
Frédéric
F
Laboratory of Pathophysiology of Bone Resorption and Therapy of Primitive Bone Tumours, Université Nantes, EA 3822,1 rue Gaston Veil, 44035 Nantes cedex 1, France.
Chipoy
Céline
C
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000378:metabolism; D001862:Bone Resorption / Q000188:drug therapy / Q000378:metabolism; D016207:Cytokines / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D009569:Nitric Oxide / Q000037:antagonists & inhibitors / Q000096:biosynthesis; D014157:Transcription Factors / Q000378:metabolism
D000893:Anti-Inflammatory Agents; D000970:Antineoplastic Agents; D016207:Cytokines; D056572:Histone Deacetylase Inhibitors; D014157:Transcription Factors; D009569:Nitric Oxide